Gaudium IVF

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE0P8B01020
  • NSEID: GAUDIUMIVF
  • BSEID: 544709
INR
116.95
-2.35 (-1.97%)
BSENSE

May 27

BSE+NSE Vol: 2.35 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.35 lacs (17.01%) Volume

Shareholding (Mar 2026)

FII

6.70%

Held by 6 FIIs

DII

2.63%

Held by 2 DIIs

Promoter

71.29%

Why is Gaudium IVF and Women Health Ltd falling/rising?

28-May-2026

As of 27-May, Gaudium IVF and Women Health Ltd's stock price is currently at 116.95, reflecting a decline of 1.97% and an 8.76% drop over the past month. Despite recent underperformance and decreasing investor participation, the stock remains above its moving averages, indicating better long-term performance.

As of 27-May, Gaudium IVF and Women Health Ltd's stock price is falling, currently at 116.95, which reflects a decrease of 2.35 or 1.97%. The stock has underperformed its sector by 2.37% today and has experienced a consecutive decline over the last two days, resulting in a total drop of 2.38% during this period. Additionally, the stock has shown a significant decline over the past month, with a decrease of 8.76%, despite a positive performance of 3.91% over the last week.<BR><BR>Investor participation appears to be waning, as evidenced by a delivery volume of 22.02k on 26 May, which has decreased by 7.54% compared to the 5-day average. This decline in trading activity may contribute to the downward pressure on the stock price. However, it is noteworthy that Gaudium IVF is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that while the stock is currently falling, it has been performing relatively well over a longer time frame.

View full answer

Which are the latest news on Gaudium IVF?

28-May-2026
No latest news for Gaudium IVF found.

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 868 Cr (Micro Cap)

stock-summary
P/E

46.00

stock-summary
Industry P/E

61

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.27

stock-summary
Return on Equity

41.01%

stock-summary
Price to Book

19.22

Revenue and Profits:
Net Sales:
25 Cr
(Quarterly Results - Dec 2025)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
45.32%
0%
45.32%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Gaudium IVF for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

23-May-2026 | Source : BSE

Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

22-May-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Audited Standalone and Consolidated Financial Statements/Results of the Company for the quarter and year ended March 31 2026 is scheduled for Friday May 29 2026 at 12:00 P.M. IST.

Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of The Audited Standalone And Consolidated Financial Statements/Results Of The Company For The Quarter And Year Ended March 31 2026.

22-May-2026 | Source : BSE

Gaudium IVF And Women Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial Statements/Results of the Company for the quarter and year ended March 31 2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

(28 May 2026)

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
19.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
24.53%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.32%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
46
Industry P/E
61
Price to Book Value
18.74
EV to EBIT
33.40
EV to EBITDA
30.99
EV to Capital Employed
14.98
EV to Sales
14.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
44.85%
ROE (Latest)
41.01%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Mildly Bullish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 6 FIIs (6.7%)

Promoter with highest holding

Manika Khanna (70.73%)

Highest Public shareholder

Mukul Mahavir Agrawal (3.43%)

Individual Investors Holdings

14.67%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -38.17% vs 64.52% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -64.78% vs 169.55% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.19",
          "val2": "22.95",
          "chgp": "-38.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.83",
          "val2": "13.28",
          "chgp": "-56.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.12",
          "val2": "0.51",
          "chgp": "119.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.18",
          "val2": "9.03",
          "chgp": "-64.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.09%",
          "val2": "57.86%",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Gaudium IVF"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Gaudium IVF"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 12.98% vs 18.65% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 11.96% vs 25.49% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "59.00",
          "val2": "52.22",
          "chgp": "12.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.86",
          "val2": "25.07",
          "chgp": "11.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.39",
          "val2": "0.54",
          "chgp": "157.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "18.63",
          "val2": "16.64",
          "chgp": "11.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "47.22%",
          "val2": "48.01%",
          "chgp": "-0.79%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
14.19
22.95
-38.17%
Operating Profit (PBDIT) excl Other Income
5.83
13.28
-56.10%
Interest
1.12
0.51
119.61%
Exceptional Items
0.00
0.00
Standalone Net Profit
3.18
9.03
-64.78%
Operating Profit Margin (Excl OI)
41.09%
57.86%
-16.77%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -38.17% vs 64.52% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -64.78% vs 169.55% in Sep 2025

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
59.00
52.22
12.98%
Operating Profit (PBDIT) excl Other Income
27.86
25.07
11.13%
Interest
1.39
0.54
157.41%
Exceptional Items
0.00
0.00
Standalone Net Profit
18.63
16.64
11.96%
Operating Profit Margin (Excl OI)
47.22%
48.01%
-0.79%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 12.98% vs 18.65% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 11.96% vs 25.49% in Mar 2024

stock-summaryCompany CV
About Gaudium IVF and Women Health Ltd stock-summary
stock-summary
Gaudium IVF and Women Health Ltd
Micro Cap
Healthcare Services
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available